New Formulation of Trimethoprim Injectable Solution for Veterinary Use
Article Sidebar
Main Article Content
Abstract
The aim of this study was prepared new formulation of trimethoprim injectable
solution in the Physiology and pharmacology department /College ofVeterinary
Medicine, University of Baghdad.Trimethoprim injection formulation is antibacterial and
used against a number of bacteria, protozoa and Rickettsia. Data was collected about the
materials used in the preparation of the formula from the well-known pharmacopeia,
including the specification, physical and chemical properties of active ingredient, the
additive and preservative that must be used. Three pilot formulae were prepared from
analar chemical ingredient from which one formula was chosen and tested to approve its
quantitative and qualitative specification. Quantitative evaluation, stability of the
formula was also tested under different storage environmental condition of low and high
temperature at different periods through and one year and through the questionnaire field.
Questionnaire proved the product, stability and therapeutic efficiency. The composition
obtained a certificate of acceptance from the Veterinary State Company and Veterinary
Drug Research and production Centre as new preparation Formula of Trimethoprim
Injectable Solution for Veterinary use.
Downloads
Article Details
How to Cite
References
Brumfitt W and Hamilton-Miller JM (1993). "Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines". J Chemother5 (6): 465–469.
Lawrenson RA and Logie JW (2001). "Antibiotic failure in the treatment of urinary tract infections in young women". J AntimicrobChemother48 (6): 895–901.
Bean DC Livermore DM Papa I and Hall LM (2005). "Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man". J AntimicrobChemother56 (5): 962–964.
Gilbert DN Moellering RC Eliopoulos GM Chambers HF and Saag MS.(2009). The Sanford Guide to Antimicrobial Therapy. 39th edition. Sperryville, VA: Antimicrobial Therapy, Inc. 568-574.
Grose WE, Bodey GP, Loo TL.( 2010). Clinical Pharmcology of Intravenously Administered Trimethoprim-Sulfamethoxazole. Antimicrob Agents chemother.;24:588-595.
Teva Pharmaceuticals Customer Service (personal communications),(2010) February 18, and March 16 and March 30, May 10, June 16, July 20, August 3, 16, and 30, September 28, October 27, November 10, and December 7, (2010); and January 12, 2011.
Zimmer SM SchuetzAN and Franco-Paredes C. (2007). Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin Infect Dis. 44(3):466-467.
Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic Susceptibility Testing by a Standardized Single Disk Method. Am J ClinPathol Apr. 2005;55: 812-816.
Stenbk JB (2000) Mender Ship of the British Pharmacopoeia Commission, British Pharmacopoeia (Veterinary).1045-1088.
Murray L ed. (2009) Red Book. Montvale,NJ: Thomson PDR;. 129-137.
Sulfamethoxazole and Trimethoprim Injection product information. (2009). Teva Parenteral Medicines; 456-470.
McEvoy GK Snow EK Miller J eds AHFS (2010) Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 122-145.
JodlowskiTZ Melnychuk I and Conry J (2007).Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother.
(10):1694-1699.
Maraki S Scoulica E Nioti E and Tselentis Y (2009).Nocardial infection in Crete, Greece: review of fifteen cases from 2003 to 2007. Scand J Infect Dis. 41(2):122-127.
Cheng AC and Currie BJ. (2005). Melioidosis: epidemiology, pathophysiology, and management. ClinMicrobiol Rev. 18(2):383-416.
Verdier RI Fitzgerald DW Johnson WD Jr and Pape JW (2000).Trimethoprimsulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclosporacayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med. 132(11):885-888.
Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society
of America. MMWR Recomm Rep. 2004; 53(RR-15):1-112.
Currie BJ (2005). Burkholderiapseudomallei and Burkholderia mallei: melioidosis and glanders. In: Mandell GL, Bennett JE, Dolin D, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 2. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2622-2632.
Maschmeyer G and Göbel UB. (2005). Stenotrophomonasmaltophilia and Burkholderiacepacia. In: Mandell GL, Bennett JE, Dolin D, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 2. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone;:2615-2622.
Nicodemo AC and Paez JI. (2007). Antimicrobial therapy for Stenotrophomonasmaltophilia infections. Eur J ClinMicrobiol Infect Dis. 26(4):229-237.
Falagas ME Valkimadi PE Huang YT Matthaiou DK and Hsueh PR (2008). Therapeutic options for Stenotrophomonasmaltophilia infections beyond cotrimoxazole: a systematic review. J AntimicrobChemother. 62(5):889-894